BioCentury
ARTICLE | Top Story

Bayer and CuraGen in two alliances

January 16, 2001 8:00 AM UTC

Bayer (DAX:BAYG) and CRGN entered two drug development alliances. Under a 15-year obesity and diabetes agreement, CRGN will deliver to BAYG 80 targets validated by CRGN's functional genomics and bioinformatics technologies during the first five years. BAYG will use its high-throughput screening, combinatorial chemistry and medicinal chemistry and pharmacology to develop small molecules against the targets, and will conduct early stage preclinical development. CRGN will also conduct pharmacogenomic and toxicogenomic studies to select and prioritize lead compounds. Following compound optimization, CRGN will genotype patient populations using its SNPCalling technology to identify the most appropriate patients for treatment. BAYG and CRGN expect to bring 12 candidates to clinical development. The companies will share R&D and commercialization costs of up to $1.34 billion. BAYG and CRGN said that R&D costs will be split at a 56:44 ratio, and the companies will jointly commercialize resulting therapeutics and share profits according to their contributions. ...